Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Mental Retardation-linked Nonsense Mutation in Cereblon Is Rescued by Proteasome Inhibition

(2013) Guoqiang Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanisms and function of substrate recruitment by F-box proteins

(2013) Jeffrey R. Skaar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy

(2013) J Shortt et al.   ONCOGENE

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

(2012) Alexander L. Ruchelman et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A Temporal Chromatin Signature in Human Embryonic Stem Cells Identifies Regulators of Cardiac Development

(2012) Sharon L. Paige et al.   CELL

The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2 stability

(2012) Ling Zhang et al.   CELL CYCLE

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

(2012) Sandra Roche et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

The application and biology of immunomodulatory drugs (IMiDs) in cancer

(2012) Beiqing Pan et al.   PHARMACOLOGY & THERAPEUTICS

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

The Molecular Basis of CRL4DDB2/CSA Ubiquitin Ligase Architecture, Targeting, and Activation

(2011) Eric S. Fischer et al.   CELL

Detecting UV-lesions in the genome: The modular CRL4 ubiquitin ligase does it best!

(2011) Andrea Scrima et al.   FEBS LETTERS

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

(2011) Craig C. Hofmeister et al.   JOURNAL OF CLINICAL ONCOLOGY

PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse

(2011) P. V. Hornbeck et al.   NUCLEIC ACIDS RESEARCH

Further evidence for the possible role ofMEIS2in the development of cleft palate and cardiac septum

(2010) Moira A. Crowley et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Dynamics of Cullin-RING Ubiquitin Ligase Network Revealed by Systematic Quantitative Proteomics

(2010) Eric J. Bennett et al.   CELL

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

A promiscuous α-helical motif anchors viral hijackers and substrate receptors to the CUL4–DDB1 ubiquitin ligase machinery

(2009) Ti Li et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural Basis of UV DNA-Damage Recognition by the DDB1–DDB2 Complex

(2008) Andrea Scrima et al.   CELL